The Fc-modified humanized anti-CD19 monoclonal antibody tafasitamab, combined with the immunomodulatory drug lenalidomide, was demonstrated to be effective and well-tolerated for autologous stem cell transplant (ASCT)-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the single-arm phase II L-MIND study (NCT02399085) [1]. Here, CD19 is linked to diffuse large B-cell lymphoma.